These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33497547)

  • 21. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
    Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
    Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.
    Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE
    Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT.
    Strang J; Kelleher M; Mayet S; Day E; Hellier J; Byford S; Murphy C; McLennan B; Shearer J; Ryan E; Marsden J
    Health Technol Assess; 2019 Jan; 23(3):1-72. PubMed ID: 30702059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
    Hollander P; Gupta AK; Plodkowski R; Greenway F; Bays H; Burns C; Klassen P; Fujioka K;
    Diabetes Care; 2013 Dec; 36(12):4022-9. PubMed ID: 24144653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence.
    Grant JE; Odlaug BL; Kim SW
    Eur Neuropsychopharmacol; 2010 Nov; 20(11):823-8. PubMed ID: 20655182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility and acceptability of a phase II randomized pharmacologic intervention for methamphetamine dependence in high-risk men who have sex with men.
    Das M; Santos D; Matheson T; Santos GM; Chu P; Vittinghoff E; Shoptaw S; Colfax GN
    AIDS; 2010 Apr; 24(7):991-1000. PubMed ID: 20397286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.
    Stoops WW; Pike E; Hays LR; Glaser PE; Rush CR
    Pharmacol Biochem Behav; 2015 Feb; 129():45-50. PubMed ID: 25459104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
    Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
    N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.
    Comer SD; Sullivan MA; Yu E; Rothenberg JL; Kleber HD; Kampman K; Dackis C; O'Brien CP
    Arch Gen Psychiatry; 2006 Feb; 63(2):210-8. PubMed ID: 16461865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.
    Runarsdottir V; Hansdottir I; Tyrfingsson T; Einarsson M; Dugosh K; Royer-Malvestuto C; Pettinati H; Khalsa J; Woody GE
    J Addict Med; 2017; 11(3):197-204. PubMed ID: 28379861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial.
    Coffin PO; Santos GM; Hern J; Vittinghoff E; Walker JE; Matheson T; Santos D; Colfax G; Batki SL
    JAMA Psychiatry; 2020 Mar; 77(3):246-255. PubMed ID: 31825466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.
    Sullivan MA; Bisaga A; Pavlicova M; Carpenter KM; Choi CJ; Mishlen K; Levin FR; Mariani JJ; Nunes EV
    Am J Psychiatry; 2019 Feb; 176(2):129-137. PubMed ID: 30336703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
    Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
    Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence.
    Heinzerling KG; Gadzhyan J; van Oudheusden H; Rodriguez F; McCracken J; Shoptaw S
    J Adolesc Health; 2013 Apr; 52(4):502-5. PubMed ID: 23333007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use.
    Heinzerling KG; Swanson AN; Hall TM; Yi Y; Wu Y; Shoptaw SJ
    Addiction; 2014 Nov; 109(11):1878-86. PubMed ID: 24894963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.
    Kohno M; Dennis LE; McCready H; Schwartz DL; Hoffman WF; Korthuis PT
    Drug Alcohol Depend; 2018 Nov; 192():186-192. PubMed ID: 30266003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mirtazapine to reduce methamphetamine use: a randomized controlled trial.
    Colfax GN; Santos GM; Das M; Santos DM; Matheson T; Gasper J; Shoptaw S; Vittinghoff E
    Arch Gen Psychiatry; 2011 Nov; 68(11):1168-75. PubMed ID: 22065532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.